摘要
背景与目的PET已广泛应用于非小细胞肺癌的诊断及监测、治疗后评价、随访。但PET在非小细胞肺癌患者预后判断中的意义尚不是十分明确。本研究探讨18F-FDGPET显像在非小细胞肺癌患者预后判断中的价值。方法对66例非小细胞肺癌患者PET中原发病灶和转移病灶最高SUV(标准化摄取比)对患者生存的预测价值进行分析。结果原发病灶最高SUV为(6.3±3.2),全部转移病灶最高SUV为(4.3±3.1),肺门纵隔淋巴结转移灶最高SUV为(4.6±3.4)。原发灶最高SUV≥7组和<7组的总生存期分别为26.1个月和38.7个月(P=0.02)。淋巴结转移灶最高SUV≥5和<5患者的生存期分别为17.0个月和28.9个月(P<0.001)。单因素分析显示原发病灶SUV、淋巴结转移灶SUV、肿瘤分期、肿瘤的病理类型、分化程度、是否接受手术治疗、转移器官个数、PET发现淋巴结转移、PET发现骨转移是非小细胞肺癌的预后影响因素。多因素分析显示PET检查时是否发现转移病灶,是否接受手术治疗以及肿瘤病理高分化是非小细胞肺癌生存的独立预后因素。结论非小细胞肺癌患者确诊时PET检查中原发灶最高SUV、转移淋巴结最高SUV可以作为判断非小细胞肺癌患者生存的预后因素。
Background and objective ^18F-FDG PET has been widely applied in the diagnosis, treatment evaluation and following up of NSCLC. But the usefulness of PET in the prognosis predicting of NSCLC is uncertain. The purpose of the study is to investigate the value of ^18F-FDG PET in the prognosis of NSCLC. Methods The value of SUV of primary and metastasis lesions to the prognosis of NSCLC were analyzed. Results SUV of primary lesions, all the metastasis lesions and hilar and/or mediastinal metastatic lymphnodes were （6.3 ± 3.2）, （4.3 ± 3.1） and （4.6 ±3.4） respectively. Overall survival （OS） of patients whose SUV of primary lesions≥ 7 and〈 7 ones were 26.1 and 38.7 months （P=0.02）. OS of patients whose SUV of lymphnodes metastasis≥ 5 and〈 5 ones were 17.0 and 28.9 months （P〈0.001）. Kaplen-Meier survival analysis revealed that SUV of primary lcsions≥ 7, SUV of lymphnodes metastasis≥ 5, cancer stage, pathological status of tumor, differentiation of tumor, receiving surgery or not, numbers of organs that had metastasis, lymphnodes metastasis positive or not in PET scan, bone metastasis positive or not in PET scan were prognostic factors of NSCLC. Multivariate analysis suggested that tumor metastasis positive or not at PET scan, receiving surgery or not and the differentiation status was well-differentiated or not are independent prognostic factors of NSCLC patients. Conclusion SUV of primary lesions and hilar and/or mediastinal lymphnodes in newly diagnosed NSCLC can be prognostic factors for NSCLC patients.
出处
《中国肺癌杂志》
CAS
2009年第5期417-421,共5页
Chinese Journal of Lung Cancer
